{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:14:24Z","timestamp":1791422064050,"version":"4.3.3"},"reference-count":162,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","bloodreviews.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.blre.2017.03.001","type":"journal-article","created":{"date-parts":[[2017,3,5]],"date-time":"2017-03-05T01:46:22Z","timestamp":1488678382000},"page":"251-259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell"],"prefix":"10.1016","volume":"31","author":[{"given":"B","family":"Tessoulin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Eveillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Lok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Chiron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Amiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Moreau-Aubry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Le Gouill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Pellat-Deceunynck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.blre.2017.03.001_bb0005","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nrc2012","article-title":"Regulating the p53 pathway: in vitro hypotheses, in vivo veritas","volume":"6","author":"Toledo","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.blre.2017.03.001_bb0010","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"15","key":"10.1016\/j.blre.2017.03.001_bb0015","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1101\/gad.12.15.2424","article-title":"Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization","volume":"12","author":"Zindy","year":"1998","journal-title":"Genes Dev."},{"issue":"7015","key":"10.1016\/j.blre.2017.03.001_bb0020","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature03098","article-title":"Intrinsic tumour suppression","volume":"432","author":"Lowe","year":"2004","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.blre.2017.03.001_bb0025","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ccr.2010.09.005","article-title":"Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53\/MDM2 autoregulatory loop in multiple myeloma development","volume":"18","author":"Pichiorri","year":"2010","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.blre.2017.03.001_bb0030","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrc3318","article-title":"MicroRNAs in the p53 network: micromanagement of tumour suppression","volume":"12","author":"Hermeking","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.blre.2017.03.001_bb0035","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.cell.2009.12.032","article-title":"USP10 regulates p53 localization and stability by deubiquitinating p53","volume":"140","author":"Yuan","year":"2010","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.blre.2017.03.001_bb0040","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2012.01.021","article-title":"ATM-dependent downregulation of USP7\/HAUSP by PPM1G activates p53 response to DNA damage","volume":"45","author":"Khoronenkova","year":"2012","journal-title":"Mol. Cell"},{"issue":"7","key":"10.1016\/j.blre.2017.03.001_bb0045","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.cell.2005.03.037","article-title":"ARF-BP1\/mule is a critical mediator of the ARF tumor suppressor","volume":"121","author":"Chen","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.blre.2017.03.001_bb0050","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","article-title":"International Agency for Research on Cancer, World Health Organization","author":"Swerdlow","year":"2008"},{"issue":"24","key":"10.1016\/j.blre.2017.03.001_bb0055","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.blre.2017.03.001_bb0060","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2012-06-435842","article-title":"MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma","volume":"121","author":"Horn","year":"2013","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.blre.2017.03.001_bb0065","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/blood-2015-05-647602","article-title":"MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA\/LYSA study","volume":"126","author":"Copie-Bergman","year":"2015","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.blre.2017.03.001_bb0070","doi-asserted-by":"crossref","first-page":"13520","DOI":"10.1073\/pnas.0804295105","article-title":"Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways","volume":"105","author":"Lenz","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.blre.2017.03.001_bb0075","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.seminhematol.2015.01.005","article-title":"The genetic landscape of diffuse large B cell lymphoma","volume":"52","author":"Pasqualucci","year":"2015","journal-title":"Semin. Hematol."},{"issue":"2","key":"10.1016\/j.blre.2017.03.001_bb0080","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2141.2006.06439.x","article-title":"Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms","volume":"136","author":"Davies","year":"2007","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.blre.2017.03.001_bb0085","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0167-9473(94)90135-X","article-title":"Multiple factor analysis (AFMULT package)","volume":"18","author":"Escofier","year":"1994","journal-title":"Comput. Statist. Data Anal."},{"issue":"1","key":"10.1016\/j.blre.2017.03.001_bb0090","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2141.2005.05405.x","article-title":"p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III\/IV","volume":"129","author":"Valga\u00f1\u00f3n","year":"2005","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.blre.2017.03.001_bb0095","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/ng.3468","article-title":"Co-occurrence of MYC amplification and TP53 mutations in human cancer","volume":"48","author":"Ulz","year":"2016","journal-title":"Nat. Genet."},{"issue":"20","key":"10.1016\/j.blre.2017.03.001_bb0100","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1101\/gad.13.20.2658","article-title":"Disruption of the ARF\u2013Mdm2\u2013p53 tumor suppressor pathway in Myc-induced lymphomagenesis","volume":"13","author":"Eischen","year":"1999","journal-title":"Genes Dev."},{"key":"10.1016\/j.blre.2017.03.001_bb0105","article-title":"A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer","volume":"23","author":"Dauch","year":"2016","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.blre.2017.03.001_bb0110","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/cr.2010.16","article-title":"Slaying RAS with a synthetic lethal weapon","volume":"20","author":"Bommi-Reddy","year":"2010","journal-title":"Cell Res."},{"issue":"5","key":"10.1016\/j.blre.2017.03.001_bb0115","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2013-05-504340","article-title":"Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy","volume":"123","author":"Mulligan","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2017.03.001_bb0120","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/bjh.13258","article-title":"RAS mutation status and bortezomib therapy for relapsed multiple myeloma","volume":"169","author":"Smith","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.blre.2017.03.001_bb0125","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/bies.200800234","article-title":"B-cell acute lymphoblastic leukaemia: towards understanding its cellular origin","volume":"31","author":"Cobaleda","year":"2009","journal-title":"Bioessays"},{"issue":"1","key":"10.1016\/j.blre.2017.03.001_bb0130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc969","article-title":"Targeting RAS signalling pathways in cancer therapy","volume":"3","author":"Downward","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"5659","key":"10.1016\/j.blre.2017.03.001_bb0135","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"issue":"15","key":"10.1016\/j.blre.2017.03.001_bb0140","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood-2012-12-473702","article-title":"MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program","volume":"122","author":"Xu-Monette","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2017.03.001_bb0145","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2017.03.001_bb0150","first-page":"529","article-title":"Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A","volume":"88","author":"Elnenaei","year":"2003","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.blre.2017.03.001_bb0155","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.blre.2017.03.001_bb0160","doi-asserted-by":"crossref","first-page":"11091","DOI":"10.1038\/ncomms11091","article-title":"p53 downregulates the Fanconi anaemia DNA repair pathway","volume":"7","author":"Jaber","year":"2016","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.blre.2017.03.001_bb0165","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1182\/blood-2014-01-548800","article-title":"PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH\/ROS balance","volume":"124","author":"Tessoulin","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2017.03.001_bb0170","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nchembio.1965","article-title":"CRISPR-Cas9-based target validation for p53-reactivating model compounds","volume":"12","author":"Wanzel","year":"2016","journal-title":"Nat. Chem. Biol."},{"issue":"14","key":"10.1016\/j.blre.2017.03.001_bb0175","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1182\/blood-2010-11-317438","article-title":"ABT-737 is highly effective against molecular subgroups of multiple myeloma","volume":"118","author":"Bodet","year":"2011","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.blre.2017.03.001_bb0180","doi-asserted-by":"crossref","first-page":"5973","DOI":"10.1158\/1078-0432.CCR-11-0955","article-title":"ABT-737 induces apoptosis in mantle cell lymphoma cells with a bcl-2high\/mcl-1low profile and synergizes with other antineoplastic agents","volume":"17","author":"Touzeau","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"25","key":"10.1016\/j.blre.2017.03.001_bb0185","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2016-01-688796","article-title":"The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism","volume":"127","author":"Anderson","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2017.03.001_bb0190","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.exphem.2014.10.004","article-title":"Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach","volume":"43","author":"Kiebala","year":"2015","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.blre.2017.03.001_bb0195","series-title":"Abstract N 310: the oncolytic measles virus preferentially infects p53 abnormal myeloma cells [Internet]","author":"Lok","year":"2016"},{"issue":"2","key":"10.1016\/j.blre.2017.03.001_bb0200","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.foodqual.2013.04.013","article-title":"Handling missing values in multiple factor analysis","volume":"30","author":"Husson","year":"2013","journal-title":"Food Quality and Preference"},{"issue":"4","key":"10.1016\/j.blre.2017.03.001_bb0205","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/cncr.21687","article-title":"K-Ras mutations and N-ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements","volume":"106","author":"Liang","year":"2006","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.blre.2017.03.001_bb0210","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","article-title":"Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial","volume":"109","author":"Moorman","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2017.03.001_bb0215","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.7150\/jca.11959","article-title":"CDKN2 gene deletion as poor prognosis predictor involved in the progression of adult B-lineage acute lymphoblastic leukemia patients","volume":"6","author":"Xu","year":"2015","journal-title":"J. Cancer"},{"issue":"2","key":"10.1016\/j.blre.2017.03.001_bb0220","doi-asserted-by":"crossref","first-page":"e0148972","DOI":"10.1371\/journal.pone.0148972","article-title":"Genome-wide DNA copy number analysis of acute lymphoblastic leukemia identifies new genetic markers associated with clinical outcome","volume":"11","author":"Forero-Castro","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.blre.2017.03.001_bb0225","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1057::AID-CNCR16>3.0.CO;2-6","article-title":"ATM gene deletion in patients with adult acute lymphoblastic leukemia","volume":"88","author":"Haidar","year":"2000","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.blre.2017.03.001_bb0230","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/humu.9140","article-title":"ATM gene alterations in childhood acute lymphoblastic leukemias","volume":"21","author":"Gumy Pause","year":"2003","journal-title":"Hum. Mutat."},{"issue":"2","key":"10.1016\/j.blre.2017.03.001_bb0235","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/blood-2014-02-558833","article-title":"TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis","volume":"124","author":"Stengel","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2017.03.001_bb0240","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2014.229","article-title":"Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia","volume":"29","author":"DeAngelo","year":"2015","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.blre.2017.03.001_bb0245","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1038\/leu.2009.137","article-title":"B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures","volume":"23","author":"Del Giudice","year":"2009","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.blre.2017.03.001_bb0250","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1309\/AJCPUBHM8U7ZFLOB","article-title":"Aberrations of MYC are a common event in B-cell prolymphocytic leukemia","volume":"142","author":"Flatley","year":"2014","journal-title":"Am. J. Clin. Pathol."},{"issue":"6","key":"10.1016\/j.blre.2017.03.001_bb0255","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1182\/blood.V89.6.2015","article-title":"p53 Abnormalities in B-cell prolymphocytic leukemia","volume":"89","author":"Lens","year":"1997","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2017.03.001_bb0260","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3109\/10428190109097717","article-title":"A multicentric study of 41 cases of B-prolymphocytic leukemia: two evolutive forms: the Groupe Fran\u00e7ais d'H\u00e9matologie Cellulaire","volume":"42","author":"Hercher","year":"2001","journal-title":"Leuk. Lymphoma"},{"issue":"19","key":"10.1016\/j.blre.2017.03.001_bb0265","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1182\/blood-2013-07-517177","article-title":"The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells","volume":"123","author":"Zhang","year":"2014","journal-title":"Blood"},{"issue":"45","key":"10.1016\/j.blre.2017.03.001_bb0270","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Be\u00e0","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.blre.2017.03.001_bb0275","doi-asserted-by":"crossref","first-page":"680","DOI":"10.3324\/haematol.12330","article-title":"Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations","volume":"93","author":"Sander","year":"2008","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.blre.2017.03.001_bb0280","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","article-title":"High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma","volume":"126","author":"Delfau-Larue","year":"2015","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.blre.2017.03.001_bb0285","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1182\/blood-2004-10-3907","article-title":"Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome","volume":"105","author":"Rubio-Moscardo","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2017.03.001_bb0290","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.blre.2017.03.001_bb0295","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/sj.leu.2403676","article-title":"Absence of ATM hypermethylation in mantle cell and follicular lymphoma","volume":"19","author":"Chim","year":"2005","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.blre.2017.03.001_bb0300","doi-asserted-by":"crossref","first-page":"5372","DOI":"10.1073\/pnas.0831102100","article-title":"Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma","volume":"100","author":"Fang","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.blre.2017.03.001_bb0305","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1073\/pnas.0510441103","article-title":"Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma","volume":"103","author":"Greiner","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.blre.2017.03.001_bb0310","first-page":"1141","article-title":"p53 and mdm2 in mantle cell lymphoma in leukemic phase","volume":"87","author":"Solenthaler","year":"2002","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.blre.2017.03.001_bb0315","first-page":"699","article-title":"Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma","volume":"36","author":"Stefancikova","year":"2010","journal-title":"Int. J. Oncol."},{"issue":"12","key":"10.1016\/j.blre.2017.03.001_bb0320","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2011.162","article-title":"Impact of TP53 mutation and 17p deletion in mantle cell lymphoma","volume":"25","author":"Halld\u00f3rsd\u00f3ttir","year":"2011","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.blre.2017.03.001_bb0325","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1007\/s12032-011-0096-5","article-title":"TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage","volume":"29","author":"Dong","year":"2011","journal-title":"Med. Oncol."},{"issue":"10","key":"10.1016\/j.blre.2017.03.001_bb0330","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1182\/blood.V87.10.4302.bloodjournal87104302","article-title":"p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis","volume":"87","author":"Greiner","year":"1996","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2017.03.001_bb0335","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1182\/blood.V87.8.3351.bloodjournal8783351","article-title":"p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas","volume":"87","author":"Hernandez","year":"1996","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2017.03.001_bb0340","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3324\/haematol.10891","article-title":"Increased MDM2 expression is associated with inferior survival in mantle cell lymphoma, but not related to the MDM2 SNP309","volume":"92","author":"Hartmann","year":"2007","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.blre.2017.03.001_bb0345","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3324\/haematol.2011.055715","article-title":"The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index","volume":"97","author":"Slotta-Huspenina","year":"2012","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.blre.2017.03.001_bb0350","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s00277-014-2049-5","article-title":"Mantle cell lymphoma epidemiology: a population-based study in France","volume":"93","author":"Leux","year":"2014","journal-title":"Ann. Hematol."},{"issue":"10044","key":"10.1016\/j.blre.2017.03.001_bb0355","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"issue":"7574","key":"10.1016\/j.blre.2017.03.001_bb0360","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"issue":"14","key":"10.1016\/j.blre.2017.03.001_bb0365","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1158\/1078-0432.CCR-11-2342","article-title":"Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia","volume":"18","author":"Brown","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.blre.2017.03.001_bb0370","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1182\/blood-2015-05-647578","article-title":"Presence of multiple recurrent mutations confers poor trial outcome of relapsed\/refractory CLL","volume":"126","author":"Gui\u00e8ze","year":"2015","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.blre.2017.03.001_bb0375","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1200\/JCO.2011.41.0852","article-title":"Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom leukemia research fund chronic lymphocytic leukemia 4 trial","volume":"30","author":"Skowronska","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.blre.2017.03.001_bb0380","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1182\/blood-2012-04-423517","article-title":"High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations","volume":"120","author":"Edelmann","year":"2012","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.blre.2017.03.001_bb0385","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","article-title":"TP53 mutation and survival in chronic lymphocytic leukemia","volume":"28","author":"Zenz","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.blre.2017.03.001_bb0390","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/sj.leu.2404195","article-title":"Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment","volume":"20","author":"Trbusek","year":"2006","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.blre.2017.03.001_bb0395","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.blre.2017.03.001_bb0400","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129544","article-title":"Comprehensive analysis of disease-related genes in chronic lymphocytic leukemia by multiplex pcr-based next generation sequencing","volume":"10","author":"Vollbrecht","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.blre.2017.03.001_bb0405","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1182\/blood.V98.3.814","article-title":"p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative toTP53 mutation","volume":"98","author":"Pettitt","year":"2001","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2017.03.001_bb0410","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2008-04-154070","article-title":"Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up","volume":"112","author":"Zenz","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2017.03.001_bb0415","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/blood-2015-02-585042","article-title":"Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia","volume":"126","author":"Gui\u00e8ze","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2017.03.001_bb0420","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","article-title":"Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial","volume":"127","author":"Fischer","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2017.03.001_bb0425","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.blre.2017.03.001_bb0430","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood.V80.3.758.758","article-title":"MYC rearrangements in histologically progressed follicular lymphomas","volume":"80","author":"Yano","year":"1992","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2017.03.001_bb0435","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/10428190701836845","article-title":"C-MYC translocation in t(14;18) positive follicular lymphoma at presentation: an adverse prognostic indicator?","volume":"49","author":"Christie","year":"2008","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.blre.2017.03.001_bb0440","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1016\/S0002-9440(10)65071-7","article-title":"INK4a\/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene","volume":"156","author":"Pinyol","year":"2000","journal-title":"Am. J. Pathol."},{"issue":"6","key":"10.1016\/j.blre.2017.03.001_bb0445","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/1078-0432.CCR-13-2175","article-title":"Inactivation of the CDKN2A tumor-suppressor gene by deletion or methylation is common at diagnosis in follicular lymphoma and associated with poor clinical outcome","volume":"20","author":"Alhejaily","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.blre.2017.03.001_bb0450","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1182\/blood-2013-05-500595","article-title":"Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma","volume":"123","author":"Bouska","year":"2014","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.blre.2017.03.001_bb0455","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1158\/1078-0432.CCR-07-0456","article-title":"Comprehensive analysis of copy number and allele status identifies multiple chromosome defects underlying follicular lymphoma pathogenesis","volume":"13","author":"Ross","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.blre.2017.03.001_bb0460","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/gcc.20606","article-title":"Prognostic significance of secondary cytogenetic alterations in follicular lymphomas","volume":"47","author":"Johnson","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"issue":"5","key":"10.1016\/j.blre.2017.03.001_bb0465","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1080\/10428190290021623","article-title":"Mutation of the ATM gene is not involved in the pathogenesis of either follicle center lymphoma or its transformation to higher-grade lymphoma","volume":"43","author":"Lossos","year":"2002","journal-title":"Leuk. Lymphoma"},{"issue":"9","key":"10.1016\/j.blre.2017.03.001_bb0470","first-page":"908","article-title":"Bcl-6 p53 mutations in lymphomas carrying the bcl-2\/Jh rearrangement","volume":"87","author":"Bellido","year":"2002","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.blre.2017.03.001_bb0475","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1182\/blood-2008-05-154013","article-title":"The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival","volume":"112","author":"O'Shea","year":"2008","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.blre.2017.03.001_bb0480","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1182\/blood.V122.21.509.509","article-title":"Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy","volume":"122","author":"Seymour","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2017.03.001_bb0485","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/ng.2468","article-title":"The genetic landscape of mutations in burkitt lymphoma","volume":"44","author":"Love","year":"2012","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.blre.2017.03.001_bb0490","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1038\/sj.leu.2401557","article-title":"Expression of p16INK4A and p14ARF in hematological malignancies","volume":"13","author":"Taniguchi","year":"1999","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.blre.2017.03.001_bb0495","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/sj.leu.2403254","article-title":"Inactivation of the ARF\u2013MDM-2\u2013p53 pathway in sporadic Burkitt's lymphoma in children","volume":"18","author":"Wilda","year":"2003","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.blre.2017.03.001_bb0500","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1365-2141.2012.09243.x","article-title":"TP53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases","volume":"158","author":"Leventaki","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.blre.2017.03.001_bb0505","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/bjh.13849","article-title":"The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab","volume":"172","author":"Forero-Castro","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.blre.2017.03.001_bb0510","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.3324\/haematol.2010.026831","article-title":"Detection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysis","volume":"95","author":"Scholtysik","year":"2010","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.blre.2017.03.001_bb0515","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0002-9440(10)61686-0","article-title":"Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27","volume":"159","author":"S\u00e1nchez-Beato","year":"2001","journal-title":"Am. J. Pathol."},{"issue":"12","key":"10.1016\/j.blre.2017.03.001_bb0520","doi-asserted-by":"crossref","first-page":"5413","DOI":"10.1073\/pnas.88.12.5413","article-title":"p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia","volume":"88","author":"Gaidano","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.blre.2017.03.001_bb0525","doi-asserted-by":"crossref","first-page":"e7089","DOI":"10.1371\/journal.pone.0007089","article-title":"High resolution genome-wide analysis of chromosomal alterations in Burkitt's lymphoma","volume":"4","author":"Toujani","year":"2009","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.blre.2017.03.001_bb0530","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/ng.3413","article-title":"DNA methylome analysis in Burkitt and follicular lymphomas identifies differentially methylated regions linked to somatic mutation and transcriptional control","volume":"47","author":"Kretzmer","year":"2015","journal-title":"Nat. Genet."},{"issue":"26","key":"10.1016\/j.blre.2017.03.001_bb0535","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1182\/blood-2014-03-563627","article-title":"Improved outcome of adult Burkitt lymphoma\/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial","volume":"124","author":"Hoelzer","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2017.03.001_bb0540","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.1121343109","article-title":"Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing","volume":"109","author":"Lohr","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.blre.2017.03.001_bb0545","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ng.892","article-title":"Analysis of the coding genome of diffuse large B-cell lymphoma","volume":"43","author":"Pasqualucci","year":"2011","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.blre.2017.03.001_bb0550","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/sj.leu.2401315","article-title":"Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma","volume":"13","author":"M\u00f8ller","year":"1999","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.blre.2017.03.001_bb0555","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2009-10-247122","article-title":"Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study","volume":"116","author":"Jardin","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2017.03.001_bb0560","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood-2002-02-0382","article-title":"ATM mutations are associated with inactivation of theARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma","volume":"100","author":"Gr\u00f8nb\u00e6k","year":"2002","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2017.03.001_bb0565","first-page":"908","article-title":"Deletions at 11q23 in different lymphoma subtypes","volume":"85","author":"Zhu","year":"2000","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.blre.2017.03.001_bb0570","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/gcc.22328","article-title":"Whole exome sequencing of relapsed\/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma","volume":"55","author":"Mareschal","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"issue":"19","key":"10.1016\/j.blre.2017.03.001_bb0575","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study","volume":"120","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2017.03.001_bb0580","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1182\/blood.V90.10.4078","article-title":"Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma","volume":"90","author":"Koduru","year":"1997","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.blre.2017.03.001_bb0585","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2017.03.001_bb0590","first-page":"1207","article-title":"Helicobacter pylori eradication therapy for high-grade mucosa-associated lymphoid tissue lymphomas of the stomach with analysis of p53 and K-ras alteration and microsatellite instability","volume":"18","author":"Hiyama","year":"2001","journal-title":"Int. J. Oncol."},{"issue":"5","key":"10.1016\/j.blre.2017.03.001_bb0595","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2010-01-264275","article-title":"Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome","volume":"117","author":"Rinaldi","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2017.03.001_bb0600","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/modpathol.2011.213","article-title":"Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities","volume":"25","author":"Braggio","year":"2012","journal-title":"Mod. Pathol."},{"issue":"4","key":"10.1016\/j.blre.2017.03.001_bb0605","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1007\/s13277-013-1421-8","article-title":"Detection and clinical significance of genes in primary gastrointestinal MALT lymphoma","volume":"35","author":"Zhang","year":"2013","journal-title":"Tumour Biol."},{"issue":"5","key":"10.1016\/j.blre.2017.03.001_bb0610","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/mp.51.5.262","article-title":"Analysis of the frequency of microsatellite instability and p53 gene mutation in splenic marginal zone and MALT lymphomas","volume":"51","author":"Sol Mateo","year":"1998","journal-title":"Mol. Pathol."},{"issue":"1\u20132","key":"10.1016\/j.blre.2017.03.001_bb0615","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3109\/10428190109097692","article-title":"Molecular analysis of mucosa-associated lymphoid tissue (MALT) lymphoma of ocular adnexa","volume":"42","author":"Chen","year":"2001","journal-title":"Leuk. Lymphoma"},{"issue":"2","key":"10.1016\/j.blre.2017.03.001_bb0620","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood.V96.2.410","article-title":"The gastric marginal zone B-cell lymphoma of MALT type","volume":"96","author":"Zucca","year":"2000","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2017.03.001_bb0625","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/leu.2013.365","article-title":"Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation","volume":"28","author":"Mart\u00ednez","year":"2014","journal-title":"Leukemia"},{"issue":"18","key":"10.1016\/j.blre.2017.03.001_bb0630","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1158\/1078-0432.CCR-14-2759","article-title":"Genetics and prognostication in splenic marginal zone lymphoma: revelations from deep sequencing","volume":"21","author":"Parry","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.blre.2017.03.001_bb0635","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1182\/blood-2010-02-267476","article-title":"Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group","volume":"116","author":"Salido","year":"2010","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2017.03.001_bb0640","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1365-2141.2012.09226.x","article-title":"High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma","volume":"158","author":"Fresquet","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.blre.2017.03.001_bb0645","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/leu.2014.294","article-title":"The Kr\u00fcppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma","volume":"29","author":"Piva","year":"2015","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.blre.2017.03.001_bb0650","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1084\/jem.20120904","article-title":"The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development","volume":"209","author":"Rossi","year":"2012","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.blre.2017.03.001_bb0655","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.3109\/10428194.2012.743655","article-title":"Splenic marginal zone lymphoma: a population-based study on the 2001\u20132008 incidence and survival in the United States","volume":"54","author":"Liu","year":"2013","journal-title":"Leuk. Lymphoma"},{"issue":"2","key":"10.1016\/j.blre.2017.03.001_bb0665","doi-asserted-by":"crossref","first-page":"e0149162","DOI":"10.1371\/journal.pone.0149162","article-title":"Exome sequencing in classic hairy cell leukaemia reveals widespread variation in acquired somatic mutations between individual tumours apart from the signature BRAF V(600)E lesion","volume":"11","author":"Weston-Bell","year":"2016","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.blre.2017.03.001_bb0670","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood.V83.9.2637.2637","article-title":"Hairy cell leukemia is characterized by clonal chromosome abnormalities clustered to specific regions","volume":"83","author":"Haglund","year":"1994","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2017.03.001_bb0675","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/bjh.12393","article-title":"Genome-wide high resolution DNA profiling of hairy cell leukaemia","volume":"162","author":"Rinaldi","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"21","key":"10.1016\/j.blre.2017.03.001_bb0680","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1182\/blood-2009-03-212449","article-title":"Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior","volume":"114","author":"Forconi","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2017.03.001_bb0685","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0165-4608(01)00415-0","article-title":"Chromosomal gains and losses are uncommon in hairy cell leukemia: a study based on comparative genomic hybridization and interphase fluorescence in situ hybridization","volume":"128","author":"Dierlamm","year":"2001","journal-title":"Cancer Genet. Cytogenet."},{"issue":"4","key":"10.1016\/j.blre.2017.03.001_bb0690","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/sj.leu.2401721","article-title":"p53 mutations in hairy cell leukemia","volume":"14","author":"K\u00f6nig","year":"2000","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.blre.2017.03.001_bb0695","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/bjh.12908","article-title":"Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia","volume":"166","author":"Cornet","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.blre.2017.03.001_bb0700","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstr\u00f6m's macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.blre.2017.03.001_bb0705","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3324\/haematol.2012.070458","article-title":"Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstr\u00f6m's macroglobulinemia","volume":"98","author":"Nguyen-Khac","year":"2013","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.blre.2017.03.001_bb0710","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1158\/0008-5472.CAN-08-3701","article-title":"Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappa B signaling pathways in Waldenstrom's macroglobulinemia","volume":"69","author":"Braggio","year":"2009","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.blre.2017.03.001_bb0715","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","article-title":"The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis","volume":"123","author":"Hunter","year":"2014","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.blre.2017.03.001_bb0720","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1182\/blood-2008-08-174961","article-title":"International prognostic scoring system for Waldenstr\u00f6m macroglobulinemia","volume":"113","author":"Morel","year":"2009","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.blre.2017.03.001_bb0725","doi-asserted-by":"crossref","first-page":"24205","DOI":"10.18632\/oncotarget.4434","article-title":"Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation","volume":"6","author":"Lionetti","year":"2015","journal-title":"Oncotarget."},{"issue":"33","key":"10.1016\/j.blre.2017.03.001_bb0730","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational Spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.blre.2017.03.001_bb0735","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/leu.2014.70","article-title":"Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma","volume":"28","author":"Affer","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.blre.2017.03.001_bb0740","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/j.1365-2141.2008.07281.x","article-title":"Pathogenic ATM mutations occur rarely in a subset of multiple myeloma patients","volume":"142","author":"Austen","year":"2008","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.blre.2017.03.001_bb0745","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du My\u00e9lome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2017.03.001_bb0750","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/leu.2015.287","article-title":"Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma","volume":"30","author":"Kaufman","year":"2016","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.blre.2017.03.001_bb0755","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.clml.2015.07.641","article-title":"Outcomes among high-risk and standard-risk multiple myeloma patients treated with high-dose chemotherapy and autologous hematopoietic stem-cell transplantation","volume":"15","author":"Kazmi","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"26","key":"10.1016\/j.blre.2017.03.001_bb0760","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.blre.2017.03.001_bb0765","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/humu.1177","article-title":"High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis","volume":"18","author":"Bezieau","year":"2001","journal-title":"Hum. Mutat."},{"issue":"5","key":"10.1016\/j.blre.2017.03.001_bb0770","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2008.4","article-title":"Genetic aberrations and survival in plasma cell leukemia","volume":"22","author":"Tiedemann","year":"2008","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.blre.2017.03.001_bb0775","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood.V98.10.3082","article-title":"Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors","volume":"98","author":"Avet-Loiseau","year":"2001","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.blre.2017.03.001_bb0780","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/gcc.20670","article-title":"Frequent upregulation of MYC in plasma cell leukemia","volume":"48","author":"Chiecchio","year":"2009","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"10.1016\/j.blre.2017.03.001_bb0785","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/ajh.23339","article-title":"Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles","volume":"88","author":"Mosca","year":"2013","journal-title":"Am. J. Hematol."},{"issue":"18","key":"10.1016\/j.blre.2017.03.001_bb0790","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2015.63.1929","article-title":"Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia: a prospective phase II study of the Intergroupe Francophone du My\u00e9lome","volume":"34","author":"Royer","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.blre.2017.03.001_bb0795","doi-asserted-by":"crossref","first-page":"17543","DOI":"10.18632\/oncotarget.4028","article-title":"Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns","volume":"6","author":"Cifola","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.blre.2017.03.001_bb0800","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cancergencyto.2004.05.004","article-title":"Genomic aberrations in plasma cell leukemia shown by interphase fluorescence in situ hybridization","volume":"156","author":"Chang","year":"2005","journal-title":"Cancer Genet. Cytogenet."},{"issue":"16","key":"10.1016\/j.blre.2017.03.001_bb0805","doi-asserted-by":"crossref","first-page":"21353","DOI":"10.18632\/oncotarget.7241","article-title":"Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature","volume":"7","author":"Lionetti","year":"2016","journal-title":"Oncotarget."},{"issue":"6","key":"10.1016\/j.blre.2017.03.001_bb0810","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1182\/blood-2014-03-565051","article-title":"Trends in survival of patients with primary plasma cell leukemia: a population-based analysis","volume":"124","author":"Gonsalves","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.blre.2017.03.001_bb0815","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ajh.23600","article-title":"Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: analysis of the Greek myeloma study group","volume":"89","author":"Katodritou","year":"2014","journal-title":"Am. J. Hematol."}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X16300595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X16300595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T06:49:51Z","timestamp":1601707791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X16300595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":162,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0268960X16300595"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2017.03.001","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2017.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}